| | | | | | | | | | |
|
| |
|
| Dockets Entered
On February 14, 2005
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 2004N-0366
|
| Working with Stakeholders on Scientific Opportunities for Facilitating Development of Vaccines, Blood and Blood Products, and Cellular, Tissue, and Gene Therapies
|
|
|
|
|
| 2005D-0021
|
| International Conference on Harmonisation; Draft Guidance on Q8 Pharmaceutical Development
|
|
|
|
|
| 2005N-0038
|
| Reporting of Adverse Events to Institutional Review Boards; Public Hearing
|
|
|
|
|
| 2005P-0066
|
| ANDA Suitability for Amlodipine Besylate Capsules 2.5, 5, and 10mg
|
|
| |
|
| 2004N-0366
|
| Working with Stakeholders on Scientific Opportunities for Facilitating Development of Vaccines, Blood and Blood Products, and Cellular, Tissue, and Gene Therapies
|
|
|
|
|
| NM
2
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005D-0021
|
| International Conference on Harmonisation; Draft Guidance on Q8 Pharmaceutical Development
|
|
|
|
|
| GDL
1
|
| Guidance
|
| Vol #:
|
| 1
|
|
|
|
|
| NAD
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005N-0038
|
| Reporting of Adverse Events to Institutional Review Boards; Public Hearing
|
|
|
|
|
| EC 1
|
| Dr. Rev Richard Wolberg
|
| Vol #:
|
| 1
|
|
|
|
|
| EC
2
|
| First Clinical Research
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005P-0066
|
| ANDA Suitability for Amlodipine Besylate Capsules 2.5, 5, and 10mg
|
|
|
|
|
| ACK
1
|
| DLA Piper Rudnick Gray Cary
|
| Vol #:
|
| 1
|
|
|
|
|
| CP
1
|
| DLA Piper Rudnick Gray Cary
|
| Vol #:
|
| 1
|
|
